Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer

被引:21
|
作者
Cruz-Rico, Graciela [1 ]
Aviles-Salas, Alejandro [3 ]
Segura-Gonzalez, Manuel [2 ]
Maria Espinosa-Garcia, Ana [4 ]
Alejandra Ramirez-Tirado, Laura [1 ]
Morales-Oyarvide, Vicente [2 ]
Rojas-Marin, Carlos [3 ]
Cardona, Andres-Felipe [5 ]
Arrieta, Oscar [1 ,2 ]
机构
[1] Hosp Gen Mexico City, Expt Oncol Lab, Mexico City, DF, Mexico
[2] Hosp Gen Mexico City, Clin Thorac Oncol, Mexico City, DF, Mexico
[3] Hosp Gen Mexico City, Inst Nacl Cancerol INCan, Dept Pathol, Mexico City, DF, Mexico
[4] Hosp Gen Mexico City, Gen Med Lab, Mexico City, DF, Mexico
[5] Clin Cty, Inst Oncol, Clin & Translat Oncol Grp, Bogota, Colombia
关键词
non-small cell lung carcinoma; anaplastic lymphoma kinase; routine diagnostic tests; immunohistochemistry; real-time polymerase chain reaction; ANAPLASTIC LYMPHOMA; FUSION GENE; ALK REARRANGEMENT; KINASE; ADENOCARCINOMA; CRIZOTINIB; INHIBITOR; FEATURES; IDENTIFICATION; CHEMOTHERAPY;
D O I
10.1097/COC.0000000000000213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess anaplastic lymphoma kinase (ALK) rearrangement detection with immunohistochemistry (IHC) and real-time polymerase chain reaction (RT-qPCR) in comparison with fluorescence in situ hybridization (FISH). Methods: Tumor tissue samples from 230 patients with advanced non-small cell lung cancer (NSCLC) were analyzed by FISH to detect ALK rearrangements. Additional IHC tests using 5A4 clone and RT-qPCR (variants 1 to 5) were performed in 63 and 48 patients, respectively. Results: Thirteen percent of FISH tests were not evaluable. From the remaining tests (n = 200), 18 (9.0%) were ALK positive (ALK(+)). ALK(+) patients were significantly younger at the time of diagnosis (below 55 y, 14.3% vs. 5.5%, P = 0.035), were light smokers (tobacco index < 10, 12.6% vs. 4.1%, P = 0.049), and presented adenocarcinoma with a mucinous component (30.8 vs. 8.0%, P = 0.007). When comparing FISH with IHC using a cutoff of 1 + or 2 +, and only 2 + staining intensity, the sensitivity, specificity, negative predictive value, and positive predictive value were as follows: 83.3%, 100.0%, 93.75%, and 100.0%; and 55.6%, 100.0%, 84.9%, and 100.0%, respectively. For RT-qPCR, these results were 55.6, 100, 90.7, and 100.0%, respectively. Conclusions: Our results suggest that RT-qPCR is an inadequate initial test for detecting ALK-positive lung cancer. IHC is highly useful as an initial screening test for ALK rearrangement detection in NSCLC. These results contribute to the medical literature on the establishment of IHC as a standard diagnostic test for ALK rearrangements in NSCLC.
引用
收藏
页码:631 / 638
页数:8
相关论文
共 50 条
  • [31] mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry
    Wang, Liang
    Yue, Wentao
    Zhang, Lina
    Zhao, Xiaoting
    Wang, Yue
    Xu, Shaofa
    SURGERY TODAY, 2012, 42 (05) : 419 - 425
  • [32] EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer
    Wang, Zhijie
    Zhang, Xuchao
    Bai, Hua
    Zhao, Jun
    Zhuo, Minglei
    An, Tongtong
    Duan, Jianchun
    Yang, Lu
    Wu, Meina
    Wang, Shuhang
    Wang, Yuyan
    Wu, Yilong
    Wang, Jie
    ONCOLOGY, 2012, 83 (05) : 248 - 256
  • [33] Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer
    Tao, Hong
    Shi, Liang
    Zhou, Aoxue
    Li, Hongxia
    Gai, Fei
    Huang, Zhan
    Che, Nanying
    Liu, Zhe
    LUNG CANCER, 2020, 149 : 154 - 161
  • [34] An effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer
    Kobayashi, Makoto
    Sakakibara, Tomohiro
    Inoue, Akira
    Fukuhara, Tatsuro
    Sasano, Hironobu
    Ichinose, Masakazu
    Nukiwa, Toshihiro
    RESPIRATORY INVESTIGATION, 2014, 52 (01) : 49 - 56
  • [35] Isolated central nervous system progression on Crizotinib An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
    Chun, Stephen G.
    Choe, Kevin S.
    Iyengar, Puneeth
    Yordy, John S.
    Timmerman, Robert D.
    CANCER BIOLOGY & THERAPY, 2012, 13 (14) : 1376 - 1383
  • [36] Validation of RT-PCR methodology for the diagnosis of EML4-ALK fusion gene in non-small cell lung cancer
    Huang, Shuwen
    Harris, J.
    Nonaka, D.
    Blackhall, F.
    Gaunt, L.
    Wallace, A.
    JOURNAL OF MEDICAL GENETICS, 2012, 49 : S54 - S54
  • [37] Clinical Outcomes and ALK Resistance Mutations in ALK plus Non-Small Cell Lung Cancer According to EML4-ALK Variant
    Lin, J.
    Zhu, V.
    Yoda, S.
    Yeap, B.
    Jessop, N.
    Schrock, A.
    Dagogo-Jack, I.
    Gowen, K.
    Stephens, P. J.
    Ross, J.
    Ali, S.
    Miller, V.
    Gainor, J.
    Hata, A.
    Iafrate, A.
    Ou, S.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
  • [38] Evaluation of EML4-ALK Fusion Proteins in Non-Small Cell Lung Cancer Using Small Molecule Inhibitors
    Li, Yongjun
    Ye, Xiaofen
    Liu, Jinfeng
    Zha, Jiping
    Pei, Lin
    NEOPLASIA, 2011, 13 (01): : 1 - U14
  • [39] Preselection Based on Clinical Characteristics in German Non-Small-Cell Lung Cancer Patients Screened for EML4-ALK Translocation
    Tufman, Amanda Laura Helen
    Edelmann, Martin
    Gamarra, Fernando
    Reu, Simone
    Borgmeier, Astrid
    Schroedl, Kathrin
    Zauber, Regine
    Mueller-Lisse, Ullrich
    Huber, Rudolf Maria
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (01) : 109 - 113
  • [40] Optic Neuropathy and Blindness Associated With Crizotinib for Non-Small-Cell Lung Cancer With EML4-ALK Translocation
    Chun, Stephen G.
    Iyengar, Puneeth
    Gerber, David E.
    Hogan, Robert N.
    Timmerman, Robert D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : E26 - E27